LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences
You may also be interested in...
Korea's LG Life Sciences Teams with Macrogen to Pool Genetics Databases for Personalized Medicines and Theranostics
SEOUL - South Korea's LG Life Sciences hopes to bring new life to its stalled oncology program by inking a memorandum of understanding with genomic services provider Macrogen to work together for the development and commercialization of personalized medicine using patients' genetic information
Korea's LG Life Sciences Teams with Macrogen to Pool Genetics Databases for Personalized Medicines and Theranostics
SEOUL - South Korea's LG Life Sciences hopes to bring new life to its stalled oncology program by inking a memorandum of understanding with genomic services provider Macrogen to work together for the development and commercialization of personalized medicine using patients' genetic information
Korea's Dong-A Regains Top Spot From Green Cross In Q2 Sales
SEOUL - Dong-A Pharmaceutical regained South Korea's top sales spot in the second quarter from vaccine maker Green Cross and expects to continue its sales trend through the year